Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 7088 | Ordered by Date (descending)
1 2 3 ... 69 70 71  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Umoja Biopharma–MPM Capital: investment, 202011 financing round Series A totalling $53m incl existing + co-lead investor MPM Capital 2020-11-18
Umoja Biopharma–Qiming: investment, 202011 financing round Series A totalling $53m incl new + co-lead investor Qiming 2020-11-18
Umoja Biopharma–SEVERAL: investment, 202011 financing round Series A $53m co-led by MPM Capital + Qiming Venture Parners USA 2020-11-18
Umoja Biopharma–Verge Scientific Communications: public relations, 202011 service existent by Verge 2020-11-18
Nereid Therapeutics–Apple Tree Partners: investment, 202011 investment commitment $50m Series A funding from ATP 2020-11-16
Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi 2020-11-13
m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences 2020-11-12
Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital 2020-11-12
Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer 2020-11-12
Metagenomi–HOF Capital: investment, 202011 financing round Series A totalling $65m incl co-investor HOF Capital 2020-11-12
Metagenomi–Humboldt Fund: investment, 202011 financing round Series A totalling $65m incl co-lead investor Humboldt Fund 2020-11-12
Metagenomi–InCube Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor InCube Ventures 2020-11-12
Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund 2020-11-12
Metagenomi–Sozo Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor Sozo Ventures 2020-11-12
Stargazer Pharmaceuticals–SEVERAL: investment, 202011 financing round Series A $57m with Novo Holdings + venBio + Canaan Partners + Pontifax + FFB 2020-11-09
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties 2020-11-09
Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept 2020-11-09
Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis 2020-11-06
Cytek Biosciences–SEVERAL: investment, 202011 financing round Series D $120m co-led by RA Capital + Hillhouse Capital 2020-11-05
VelosBio–Merck (US): investment, 202011– acquisition $2.75b in cash of VelosBio by Merck 2020-11-05
Sofie Biosciences–SEVERAL: investment, 202011 financing round Series C $27.4m led by Jubilant Pharma with $25m plus 3 other investors 2020-11-04
Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures 2020-11-02
Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd 2020-11-02
Fountain Healthcare Partners–SEVERAL: investment, 202011 final closing of Fund III addit €7m incl Kyowa Kirin bringing total fund to hard cap of €125m 2020-11-02
Horizon Discovery–PerkinElmer: investment, 202011– cash tender offer £296m ($383m) representing total enterprise value of £284m ($368m) 2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) 2020-11-02
Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC 2020-10-29
Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors 2020-10-28
Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share 2020-10-28
Gracell Biotechnologies–SEVERAL: investment, 202010 financing round Series C $100m led by Wellington + OrbiMed + Morningside Ventures 2020-10-28
Eagle Genomics–ETF Partners: investment, 202010 financing round totalling $9m incl investor Environmental Technologies Fund (ETF) 2020-10-27
Eagle Genomics–Granpool Innovative Investments: investment, 202010 financing round totalling $9m incl investor consortium led by Granpool 2020-10-27
Eagle Genomics–SEVERAL: investment, 202010 financing round $9m with ETF Partners + investor consortium led by Granpool II 2020-10-27
TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly 2020-10-27
TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund 2020-10-27
TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly 2020-10-27
AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones 2020-10-26
Base Genomics–Bristows: legal services, 202010 supply Bristows LLP legal advisor to Base Genomics for acquisition by Exact Sciences 2020-10-26
Base Genomics–Exact Sciences: investment, 202010 acquisition 100% of Base Genomics Ltd for $410m in cash (net of cash + certain other adjustments) 2020-10-26
Base Genomics–William Blair: financial services, 202010 supply William Blair financial advisor to Base Genomics for acquisition by Exact Sciences 2020-10-26
Exact Sciences–K&L Gates: legal services, 202010 supply legal advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier 2020-10-26
Exact Sciences–XMS Capital: financial services, 202010 supply financial advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier 2020-10-26
MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs 2020-10-26
Scorpion Therapeutics–Abingworth: investment, 202010 financing round Series A totalling $108m incl co-investor Abingworth 2020-10-26
Scorpion Therapeutics–Atlas Venture: investment, 202010 financing round Series A totalling $108m incl co-lead investor Atlas Venture 2020-10-26
Scorpion Therapeutics–Omega Funds: investment, 202010 financing round Series A totalling $108m incl co-lead investor Omega Funds 2020-10-26
Scorpion Therapeutics–Partners HealthCare: investment, 202010 financing round Series A totalling $108m incl co-investor Partners Healthcare Innovation 2020-10-26
Scorpion Therapeutics–Precision Medicine Group: public relations, 202010 service existent Stern IR is investor contact 2020-10-26
Scorpion Therapeutics–SEVERAL: investment, 202010 financing round Series A $108m led by Atlas Venture + Omega Funds + Vida Ventures 2020-10-26
Scorpion Therapeutics–Ten Bridge Communications: public relations, 202010 service existent Ten Bridge is media contact 2020-10-26
Scorpion Therapeutics–Vida Ventures: investment, 202010 financing round Series A totalling $108m incl co-lead investor Vida Ventures 2020-10-26
Thrive Earlier Detection–Exact Sciences: investment, 202010– acquisition $1.7b upfront with 35% in cash + 65% common stock plus $450m milestones 2020-10-26
Thrive Earlier Detection–Goldman Sachs: financial services, 202010 supply GS financial advisor to TED for acquisition by Exact Sciences 2020-10-26
Thrive Earlier Detection–Goodwin Procter: legal services, 202010 supply Goodwin Procter LLP legal advisor to TED for acquisition by Exact Sciences 2020-10-26
Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva 2020-10-20
Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market 2020-10-19
Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital 2020-10-19
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BIoMedPartners plus all existing investors 2020-10-19
Azitra–Bayer: investment, 202010 financing round Series B totalling $17m incl $8m from lead investor Leaps by Bayer 2020-10-15
Azitra–Bios Partners: investment, 202010 financing round Series B totalling $17m incl existing + co-investor Bios Partners 2020-10-15
Azitra–Connecticut (govt): investment, 202010 financing round Series B totalling $17m incl existing + co-investor Connecticut Innovations 2020-10-15
Azitra–SEVERAL: investment, 202010 financing round Series B $17m led by Leaps by Bayer 2020-10-15
Oribiotech–Amadeus Capital: investment, 202010 financing round Series A totalling $30m incl existing + co investor Amadeus Capital Partners 2020-10-14
Oribiotech–BAM the Agency: public relations, 202010 service existent by BAM 2020-10-14
Oribiotech–Delin Ventures: investment, 202010 financing round Series A totalling $30m incl existing + co investor Delin Ventures 2020-10-14
Oribiotech–Kindred Capital: investment, 202010 financing round Series A totalling $30m incl existing + co investor Kindred Capital 2020-10-14
Oribiotech–Northpond Ventures: investment, 202010 financing round Series A totalling $30m incl new + lead investor Northpond Ventures 2020-10-14
Oribiotech–Octopus Ventures: investment, 202010 financing round Series A totalling $30m incl new + co-lead investor Octopus Ventures 2020-10-14
Oribiotech–SEVERAL: investment, 202010 financing round Series A $30m led by Northpond Ventures alongside Octopus Ventures 2020-10-14
RayzeBio–Samsara BioCapital: investment, 202010 financing round Series A totalling $45m inc co-investor Samsara BioCapital 2020-10-14
RayzeBio–SEVERAL: investment, 202010 financing round Series A $45m co-led by venBio Partners + Versant Ventures 2020-10-14
RayzeBio–VenBio: investment, 202010 financing round Series A totalling $45m inc co-lead investor venBio Partners 2020-10-14
RayzeBio–Versant Ventures: investment, 202010 financing round Series A totalling $45m inc co-lead investor Versant Ventures 2020-10-14
Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds 2020-10-13
Chord Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum 2020-10-13
Neogene Therapeutics–Twist Bioscience: cell therapy, 202010– collab strategic partnership using DNA synthesis platform to develop T cell therapies 2020-10-13
Rappta Therapeutics–Advent Venture Partners: investment, 202010 financing round Series A totalling €9m incl co-investor Advent Life Sciences 2020-10-13
Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund 2020-10-13
Rappta Therapeutics–Novo Group: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novo Seeds 2020-10-13
Rappta Therapeutics–OTHER: investment, 202010 financing round Series A totalling €9m incl a family office as co-investor 2020-10-13
Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds 2020-10-13
Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC 2020-10-12
Kronos Bio–SEVERAL: investment, 202010 IPO $250m+$37.5m with 13.2m+2m shares common stock at $17/share at Nasdaq Global Select Market 2020-10-08
Sensei Biotherapeutics–Angermayer Group: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Apeiron Investment Group 2020-10-07
Sensei Biotherapeutics–Cambrian Biopharma: investment, 202010 financing round Series A totalling $28.5m incl co-lead investor Cambrian Biopharma 2020-10-07
Sensei Biotherapeutics–Future Ventures: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Future Ventures 2020-10-07
Sensei Biotherapeutics–H&S Ventures: investment, 202010 financing round Series A totalling $28.5m incl co-lead investor H&S Ventures 2020-10-07
Sensei Biotherapeutics–Precision Medicine Group: public relations, 202010 service existent Stern IR is investor contact 2020-10-07
Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures 2020-10-07
Sensei Biotherapeutics–Yates Network: public relations, 202010 service existent The Yates Network is media contact 2020-10-07
Federation Bio–Altitude Life Science Ventures: investment, 202010 financing round Series A totalling $50m incl existing + co-investor Altitude 2020-10-06
Federation Bio–BPCE: investment, 202010 financing round Series A totalling $50m incl new + co-investor Seventure Partners/Health for Life Capital 2020-10-06
Federation Bio–Horizons Ventures: investment, 202010 financing round Series A totalling $50m incl new + lead investor Horizons Ventures 2020-10-06
Federation Bio–Rockefeller: investment, 202010 financing round Series A totalling $50m incl existing + co-investor Venrock 2020-10-06
Federation Bio–SEVERAL: investment, 202010 financing round Series A $50m led by Horizons Ventures + incl Seventure Partners + Venrock + Altitude 2020-10-06
GSK–Nvidia: AI-based drug discovery, 202010– collab with GSK AI Hub incl supply DGX A100 systems + Clara Discovery s/w + use Cambridge-1 supercomputer 2020-10-05
ReadCoor–10x Genomics: investment, 202010– acquisition $350m in cash + shares of ReadCoor by 10x Genomics 2020-10-05
Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon 2020-10-01
Sophia Genetics–Hitachi: investment, 202010 financing round Series F totalling $110m incl co-lead investor Hitachi Ventures 2020-10-01
Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures 2020-10-01
1 2 3 ... 69 70 71  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top